[go: up one dir, main page]

MX2018003185A - Anticuerpos que se unen especificamente a tl1a. - Google Patents

Anticuerpos que se unen especificamente a tl1a.

Info

Publication number
MX2018003185A
MX2018003185A MX2018003185A MX2018003185A MX2018003185A MX 2018003185 A MX2018003185 A MX 2018003185A MX 2018003185 A MX2018003185 A MX 2018003185A MX 2018003185 A MX2018003185 A MX 2018003185A MX 2018003185 A MX2018003185 A MX 2018003185A
Authority
MX
Mexico
Prior art keywords
antibodies
tl1a
disease
cystic fibrosis
specifically bind
Prior art date
Application number
MX2018003185A
Other languages
English (en)
Inventor
Dorothy Poulton Lynn
Pollard Matthew
G Doyle Anthony
Ann Cooksey Bridget
Pande Vanya
William Clarke Adam
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2018003185A publication Critical patent/MX2018003185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sorting Of Articles (AREA)

Abstract

Variantes de anticuerpos expresadas de manera recombinante que tienen una afinidad mejorada por TL1A y una potencia mejorada con relación al anticuerpo parental del cual derivaron. Los anticuerpos inhiben la interacción entre TL1A y el receptor de muerte 3 (DR3). Los anticuerpos, o una composición con las mismas, se pueden usar para tratar uno o más entre asma, EPOC, fibrosis pulmonar, fibrosis quística, enfermedad de intestino inflamatorio, una enfermedad gastrointestinal asociada con fibrosis quística, enfermedad de Crohn, colitis, colitis ulcerosa, síndrome de intestino irritable, esofagitis eosinofílica, dermatitis atópica, eczema, escleroderma, artritis o artritis reumatoide.
MX2018003185A 2015-09-18 2016-09-16 Anticuerpos que se unen especificamente a tl1a. MX2018003185A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220442P 2015-09-18 2015-09-18
PCT/US2016/052040 WO2017049024A1 (en) 2015-09-18 2016-09-16 Antibodies that specifically bind to tl1a

Publications (1)

Publication Number Publication Date
MX2018003185A true MX2018003185A (es) 2018-08-01

Family

ID=57043002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003185A MX2018003185A (es) 2015-09-18 2016-09-16 Anticuerpos que se unen especificamente a tl1a.

Country Status (33)

Country Link
US (4) US10138296B2 (es)
EP (2) EP3693393A1 (es)
JP (2) JP7013366B2 (es)
KR (1) KR101998535B1 (es)
CN (1) CN108137693B (es)
AR (1) AR106055A1 (es)
AU (2) AU2016323460B2 (es)
BR (2) BR122021002400A8 (es)
CA (1) CA2997015A1 (es)
CL (1) CL2018000711A1 (es)
CO (1) CO2018003736A2 (es)
CY (1) CY1123499T1 (es)
DK (1) DK3350223T3 (es)
EA (1) EA201890756A1 (es)
ES (1) ES2810751T3 (es)
HR (1) HRP20201323T1 (es)
HU (1) HUE051496T2 (es)
IL (1) IL257761B2 (es)
LT (1) LT3350223T (es)
MA (2) MA52643A (es)
MD (1) MD3350223T2 (es)
MX (1) MX2018003185A (es)
PE (1) PE20181080A1 (es)
PH (1) PH12018500580B1 (es)
PL (1) PL3350223T3 (es)
PT (1) PT3350223T (es)
RS (1) RS60703B1 (es)
SI (1) SI3350223T1 (es)
SM (1) SMT202000500T1 (es)
TW (1) TWI703158B (es)
UA (1) UA125284C2 (es)
WO (1) WO2017049024A1 (es)
ZA (1) ZA201801427B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
BR112014007426B1 (pt) 2011-09-30 2023-01-03 Teva Pharmaceuticals Australia Pty Ltd Anticorpos contra tl1a e seus usos
EP3639841B1 (en) 2013-03-27 2023-09-06 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
AU2016364992B2 (en) * 2015-12-04 2021-12-09 University Of Iowa Research Foundation Apparatus, systems and methods for predicting, screening and monitoring of encephalopathy / delirium
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
SG11201903737PA (en) 2016-10-26 2019-05-30 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
EP3617235A4 (en) * 2017-04-28 2020-12-16 Ajinomoto Co., Inc. COMPOUND CONTAINING A SUBSTANCE HAVING AFFINITY FOR A SOLUBLE PROTEIN, CLIVABLE FRACTION, AND REACTIVE GROUP, OR SALT OF THE SAME
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
WO2020232125A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
JP7504992B2 (ja) 2019-10-24 2024-06-24 プロメテウス バイオサイエンシーズ，インク． Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用
JP2023538902A (ja) * 2020-08-19 2023-09-12 ヤンセン バイオテツク，インコーポレーテツド 操作されたリガンドを使用する材料及び方法
IL318428A (en) 2022-07-27 2025-03-01 Cephalon Llc Antibodies against TL1A for the treatment of ulcerative colitis and Crohn's disease
WO2024026386A1 (en) 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibody formulations
WO2024239006A1 (en) 2023-05-17 2024-11-21 Genentech, Inc. Anti-tl1a antibody therapeutic methods
TW202515910A (zh) * 2023-06-22 2025-04-16 美商派拉岡醫療公司 Il-17抗體組合物及使用方法
WO2024263900A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2025038473A1 (en) 2023-08-11 2025-02-20 Paragon Therapeutics, Inc. Tl1a binding antibodies and methods of use
WO2025076081A1 (en) 2023-10-03 2025-04-10 Absci Corporation Tl1a associated antibody compositions and methods of use
CN120058933A (zh) * 2023-11-30 2025-05-30 北京智仁美博生物科技有限公司 抗肿瘤坏死因子样配体1a的抗体及其用途
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
CN120424214A (zh) * 2024-02-05 2025-08-05 三生国健药业（上海）股份有限公司 一种抗tl1a抗体及其制备方法和用途
US20250376530A1 (en) 2024-05-17 2025-12-11 Genentech, Inc. Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
CN119552252B (zh) * 2025-01-16 2025-11-25 华润生物医药有限公司 抗tl1a抗体及其制备方法和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CA2536086C (en) 2003-08-20 2013-03-19 University Of Miami Inhibition of dr3 in the treatment of allergic lung inflammation
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
WO2006127900A2 (en) 2005-05-25 2006-11-30 Biogen Idec Ma Inc. Tl1a in the treatment of disease
CA2621083C (en) 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
WO2007076465A2 (en) 2005-12-23 2007-07-05 Diadexus, Inc. Cln248 antibody compositions and methods of use
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
WO2008106451A2 (en) 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
CA2705292C (en) 2007-11-13 2016-06-21 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against tl1a
WO2010118210A1 (en) 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
WO2011080314A2 (en) 2009-12-31 2011-07-07 Deutsches Krebsforschungszentrum Novel modulators of trail signalling
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
WO2012161856A1 (en) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
BR112014007426B1 (pt) 2011-09-30 2023-01-03 Teva Pharmaceuticals Australia Pty Ltd Anticorpos contra tl1a e seus usos
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
ES2689080T3 (es) 2013-01-02 2018-11-08 Glenmark Pharmaceuticals S.A. Anticuerpos que se unen a TL1A y sus usos
EP3639841B1 (en) 2013-03-27 2023-09-06 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a
BR112015024553A2 (pt) * 2013-04-05 2017-10-24 Genentech Inc anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio
KR102295125B1 (ko) 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
EP2996717A4 (en) 2013-05-17 2016-11-23 Cedars Sinai Medical Center DIFFERENT EFFECTS OF IFN-GAMMA AND IL-17 ON TL1A-MODULATED INFLAMMATION AND FIBROSIS
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
WO2015035261A1 (en) 2013-09-06 2015-03-12 Cedars-Sinai Medical Center Systems, devices and methods for anti-tl1a therapy
CA2929784C (en) 2013-11-13 2019-11-26 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
SG11201708480YA (en) 2015-04-15 2017-12-28 Biosearch Tech Inc Dual quencher probes
CN107835694A (zh) 2015-05-15 2018-03-23 西达-赛奈医疗中心 用于治疗炎症性肠病的模型、方法和组合物
EP3337509A4 (en) 2015-08-21 2019-01-02 The Children's Hospital of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
WO2017077715A1 (en) 2015-11-02 2017-05-11 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
EA039084B1 (ru) 2016-05-09 2021-12-01 Бристол-Майерс Сквибб Компани Антитела к tl1a и их применения
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CN109219620B (zh) 2016-06-09 2023-01-31 派立卡恩治疗公司 抗-tnfrsf25抗体
SG11201903737PA (en) 2016-10-26 2019-05-30 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
US10626180B2 (en) 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
RS64747B1 (sr) 2018-04-30 2023-11-30 Cedars Sinai Medical Center Postupci i sistemi za odabir i lečenje pacijenata sa inflamatornim bolestima
WO2020113116A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
WO2020232125A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
WO2021081365A1 (en) 2019-10-24 2021-04-29 Prometheus Biosciences, Inc. Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
WO2021108694A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
CA3180628A1 (en) 2020-06-03 2021-12-09 Rebecca GONSKY Treatments for a sub-population of inflammatory bowel disease patients
CA3180632A1 (en) 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Methods and systems for measuring post-operative disease recurrence
EP4171632A2 (en) 2020-06-26 2023-05-03 Pfizer Inc. Methods of treating inflammatory bowel disease with tl1a antibodies
WO2022103961A1 (en) 2020-11-13 2022-05-19 Prometheus Biosciences, Inc. Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4256086A4 (en) 2020-12-01 2025-01-15 Cedars-Sinai Medical Center METHODS AND SYSTEMS FOR STRATIFICATION OF PATIENTS WITH INFLAMMATORY DISEASES
CA3202510A1 (en) 2020-12-21 2022-06-30 Dermot P. Mcgovern Tl1a therapy compositions and methods of treatment therewith
US20240336691A1 (en) 2021-02-18 2024-10-10 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the lung
AU2022223420A1 (en) 2021-02-18 2023-09-21 Cedars-Sinai Medical Center Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
WO2022232253A1 (en) 2021-04-28 2022-11-03 Cedars-Sinai Medical Center Patient selection methods and kits for therapies targeting tl1a
WO2023102051A1 (en) 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Intestinal mononuclear phagocytes as prognostic biomarker for crohn's disease
WO2023102071A1 (en) 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
WO2023133538A2 (en) 2022-01-07 2023-07-13 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof

Also Published As

Publication number Publication date
TW201722990A (zh) 2017-07-01
EP3350223B1 (en) 2020-06-17
EP3350223A1 (en) 2018-07-25
RS60703B1 (sr) 2020-09-30
CA2997015A1 (en) 2017-03-23
CN108137693A (zh) 2018-06-08
US10138296B2 (en) 2018-11-27
IL257761B2 (en) 2023-03-01
TWI703158B (zh) 2020-09-01
PT3350223T (pt) 2020-08-05
BR112018005407A2 (en) 2018-10-09
MA52643A (fr) 2021-03-24
BR122021002400A8 (pt) 2023-01-24
MD3350223T2 (ro) 2020-09-30
IL257761A (en) 2018-04-30
HRP20201323T1 (hr) 2020-11-27
SMT202000500T1 (it) 2020-11-10
DK3350223T3 (da) 2020-08-24
JP2018528773A (ja) 2018-10-04
PH12018500580B1 (en) 2023-01-11
US20220185902A1 (en) 2022-06-16
IL257761B (en) 2022-11-01
EP3693393A1 (en) 2020-08-12
HK1256300A1 (zh) 2019-09-20
SI3350223T1 (sl) 2020-10-30
US20190106486A1 (en) 2019-04-11
CL2018000711A1 (es) 2018-11-23
AU2023203440A1 (en) 2023-06-29
MA42825B1 (fr) 2020-09-30
CY1123499T1 (el) 2022-03-24
PE20181080A1 (es) 2018-07-05
HK1251002A1 (en) 2019-01-18
US11220549B2 (en) 2022-01-11
CO2018003736A2 (es) 2018-07-10
JP7013366B2 (ja) 2022-02-15
JP2022051771A (ja) 2022-04-01
KR20180048712A (ko) 2018-05-10
US12162946B2 (en) 2024-12-10
ZA201801427B (en) 2019-06-26
ES2810751T3 (es) 2021-03-09
LT3350223T (lt) 2020-10-26
EA201890756A1 (ru) 2018-08-31
CN108137693B (zh) 2021-11-26
AR106055A1 (es) 2017-12-06
US20250179202A1 (en) 2025-06-05
PH12018500580A1 (en) 2018-10-15
AU2016323460B2 (en) 2023-06-15
KR101998535B1 (ko) 2019-07-09
BR112018005407A8 (pt) 2023-01-24
PL3350223T3 (pl) 2021-03-08
AU2016323460A1 (en) 2018-03-29
HUE051496T2 (hu) 2021-03-01
JP7341259B2 (ja) 2023-09-08
US20170081400A1 (en) 2017-03-23
NZ740731A (en) 2024-07-26
BR122021002400A2 (es) 2018-10-09
UA125284C2 (uk) 2022-02-16
WO2017049024A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
PH12018500580A1 (en) Antibodies that specifically bind to tl1a
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
WO2015106080A3 (en) Antibodies directed against interleukin-33 (il-33)
MX392069B (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
ZA201803366B (en) Antibody molecules to april and uses thereof
PH12017500403A1 (en) Anti-il-25 antibodies and uses thereof
MX2020012816A (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
EP4477748A3 (en) Methods of making chimeric antigen receptor-expressing cells
WO2016168595A8 (en) Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
SG10201909173PA (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
HK1259368A1 (zh) Fkpa的纯化及其用於生产重组多肽的用途
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
MX2018003713A (es) Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
MA40592A (fr) Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
WO2016196638A3 (en) Pah antibodies and uses thereof
MY197821A (en) Anti-il-22r antibodies
Foniok et al. Digraph functors which admit both left and right adjoints
Guay et al. Almost cellular algebras
EP3165229B8 (en) Composition for the prevention or treatment of polycystic ovary syndrome and its related symptoms
WO2015116569A3 (en) Antibodies directed against discoidin domain receptor family, member 1 (ddr1)
MX2018005135A (es) Anticuerpos biespecificos anti-cgrp/anti-il-23 y usos de los mismos.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
Boukmiche Impediments to employ scientific research in the development of the Arab World